register | login
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2022 Medicom Conference Planning
  • Disease Areas
  • Other Medical News
  • Podcast
  • Videos
  • Education
  • About
    • Vacancies

Tag: Bladder Cancer

Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC

Presented By
Dr Sam Chang, Vanderbilt University Medical Center, TN, USA
Trial
Phase 3, QUILT-3.032
Conference
ASCO GU 2022

8 April, 2022 11:18

Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin

Presented By
Prof. Daniel Petrylak, Yale School of Medicine, CT, USA
Trial
Phase 1/2, EV-103
Conference
ASCO GU 2022

8 April, 2022 11:16

Better survival with neoadjuvant dose-dense MVAC regimen in MIBC

Presented By
Dr Christian Pfister, Rouen University Hospital, France
Trial
Phase 3, VESPER
Conference
ESMO 2021

19 November, 2021 09:25

EAU TV: The best on bladder cancer and renal cell carcinoma

Presented By
Prof. Arnulf Stenzl
Conference
EAU 2021

31 August, 2021 12:29

Best of EAU: Highlights on bladder cancer

Presented By
Prof. Morgan Rouprêt, Pitié-Salpêtrière Hospital, Paris, France
Conference
EAU 2021

31 August, 2021 12:26

ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer

Presented By
Prof. Jürgen Gschwend, Technical University Munich, Germany
Trial
Phase 3, IMvigor010, IMvigor011
Conference
10:32:15pm> hello nurse from conference

31 August, 2021 12:26

Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma

Presented By
Prof. Thomas Powles, Barts Cancer Centre, London, UK
Trial
Phase 3, DANUBE
Conference
EAU 2021

31 August, 2021 12:26

Circulating tumour cells could aid in the decision to give neoadjuvant chemotherapy

Presented By
Dr Nick Beije, Erasmus Medical Center, Rotterdam, the Netherlands
Trial
CirGuidance

31 August, 2021 12:26

Poorer outcomes in bladder cancer predicted by race/ethnicity and gender

Presented By
Dr Shaakir Hasan, New York Proton Centre, USA
Conference
ASCO GU 2021

24 March, 2021 15:03

Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results

Presented By
Dr Thomas Powles, Barts Cancer Centre, UK
Trial
Phase 3, EV-301
Conference
ASCO GU 2021

24 March, 2021 15:03

Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results

Presented By
Dr Arjun Vasant Balar, NYU Langone Medical Oncology, USA
Conference
ASCO GU 2021

24 March, 2021 15:02

Signature DNA alterations in subtypes of bladder cancer

Presented By
Dr Andrew Thomas Lenis, Memorial Sloan Kettering Cancer Centre, New York, USA
Conference
ASCO GU 2021

24 March, 2021 15:02

Better allocation of research dollars needed

Presented By
Ms Jeenan Kaiser, University of Alberta, Canada
Conference
ASCO GU 2021

24 March, 2021 15:02

Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results

Presented By
Prof. Christopher Hoimes, Case Comprehensive Cancer Center, Cleveland, USA
Trial
Phase 1, EV-103
Conference
ESMO 2019

26 November, 2019 22:23

Largest safety study of its kind with atezolizumab in metastatic bladder cancer

Presented By
Prof. Axel Merseburger, Prof. Jens Bedke
Trial
Phase 3, SAUL, IMvigor211
Conference
EAU 2019

21 May, 2019 23:38

Bladder cancer risk and early detection

Presented By
Dr Thibault De La Motte Rouge, Dr Wei Shen Tan, Dr Bas van Rhijn, Dr Francesco Soria
Trial
EDIFICE 6, DETECT 1
Conference
EAU 2019

21 May, 2019 22:44

Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer

Presented By
Prof. Jürgen Gschwend, Prof. Sergio Bracarda
Conference
EAU 2019

21 May, 2019 21:47

FGFR3 gene mutation: Favourable prognostic impact in bladder cancer

Presented By
Dr Laura Mertens, VU Amsterdam Medical Center, the Netherlands
Conference
EAU 2019

21 May, 2019 20:52

Bladder cancer in young patients

Presented By
Dr Roland Seiler, Prof. Morgan Rouprêt, Prof. Fiona Burkhard
Trial
IMvigor 210
Conference
EAU 2019

21 May, 2019 19:55

Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy

Presented By
Dr Ana Guijarro Cascales, Hospital Universitario Fundacion Alcorcon, Spain
Conference
EAU 2019

21 May, 2019 18:57

Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG

Presented By
Prof. Ashish Kamat, MD Anderson Cancer Center, Houston, USA
Trial
KEYNOTE-057, KEYNOTE-676
Conference
EAU 2019

21 May, 2019 17:01

Robot-assisted radical cystectomy or open radical cystectomy?

Presented By
Prof. Jens Bedke, Prof. Seth Lerner, Prof. James Catto
Trial
RAZOR, iROC
Conference
EAU 2019

21 May, 2019 09:05
site created by:   

© 2021 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT